Patents by Inventor Neil Bodick
Neil Bodick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220403415Abstract: The disclosure relates to pharmaceutical compositions and methods of using pharmaceutical compositions comprising effective dosages of an adenoviral-based biological delivery and expression system for use in the treatment or prevention of osteoarthritis in human or mammalian joints by long-term inducible gene expression of human or mammalian interleukin-1 receptor antagonist (IL-1Ra) in synovial cells, comprising a helper-dependent adenoviral vector containing a nucleic acid sequence encoding for human or mammalian interleukin-1 receptor antagonist (IL-1Ra), left and right inverted terminal repeats (L ITR and R ITR), the adenoviral packaging signal and non-viral, non-coding stuffer nucleic acid sequences, wherein the expression of the human or mammalian interleukin-1 receptor antagonist (IL-1Ra) gene within synovial cells is regulated by an inflammation-sensitive promoter.Type: ApplicationFiled: September 18, 2020Publication date: December 22, 2022Inventors: Scott KELLEY, Rebecca SENTER, Monika CHABICOVSKY, Emily Walsh MARTIN, Neil BODICK, Won HONG, Kris WANG, Mark DOUGLAS, John Derek JACKSON
-
Publication number: 20220296719Abstract: The present disclosure provides compositions comprising a thermosensitive hydrogel formulation of funapide and a tri-block polymer, and methods of use and manufacture of the compositions for management of acute pain or pain associated with surgical procedure.Type: ApplicationFiled: September 9, 2020Publication date: September 22, 2022Inventors: Scott KELLEY, Ujjwal JOSHI, Ami JO, John Derek JACKSON, Rebecca SENTER, Neil BODICK
-
Patent number: 10624905Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: March 27, 2018Date of Patent: April 21, 2020Assignee: Flexion Therapeutics, Inc.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20200009156Abstract: This disclosure relates to extended-release fluticasone propionate (FP) formulations that include small microparticles and/or nanoparticles and methods of using these extended-release FP formulations for treating pain and/or inflammation in a subject.Type: ApplicationFiled: March 16, 2018Publication date: January 9, 2020Inventors: Neil BODICK, John Derek JACKSON, Ujjwal JOSHI
-
Publication number: 20180311260Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: March 27, 2018Publication date: November 1, 2018Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Patent number: 9949987Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: March 15, 2017Date of Patent: April 24, 2018Assignee: Flexion Therapeutics, Inc.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20170258815Abstract: This invention relates to the use of corticosteroids in patients with diabetes, including patients with type 2 diabetes, to treat pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis without increasing or otherwise significantly impacting blood glucose concentrations in diabetic patients, and to slow, arrest or reverse structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or periarticular tissues caused by osteoarthritis or rheumatoid arthritis without increasing or otherwise impacting blood glucose concentrations. More specifically, a formulation of triamcinolone acetonide (TCA) is administered locally to diabetes patients, including type 2 diabetes patients, as a sustained release dosage form (with or without an immediate release component) that results in efficacy levels accompanied by clinically insignificant or no measurable effect on blood glucose levels.Type: ApplicationFiled: March 14, 2017Publication date: September 14, 2017Inventor: Neil Bodick
-
Publication number: 20170182068Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: March 15, 2017Publication date: June 29, 2017Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20170135957Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: January 31, 2017Publication date: May 18, 2017Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20170100411Abstract: This invention relates to compositions and methods for achieving and maintaining maximal analgesic effect following intra-articular administration of corticosteroid formulations. The invention also describes extended release, e.g., controlled- or sustained-release corticosteroid formulations, including extended release, e.g., controlled- or sustained-release formulations of triamcinolone acetonide (TCA), fluticasone propionate, cortisol, ciclesonide (monopropionate), beclometasone diproprionate, dexamethasone, flunisolide, budesonide, desisobutyryl-ciclesonide, and/or mometasone furoate, that produce a maximal analgesic effect greater than the acute analgesic effect provided by standard corticosteroid suspensions, including non-extended release corticosteroid suspensions, and that are also associated with a clinically insignificant effect on endogenous cortisol production following administration, for example, intra-articular, intrathecal, epidural, intra-bursal, or other local administration.Type: ApplicationFiled: October 13, 2016Publication date: April 13, 2017Inventors: Neil Bodick, Derek Jackson, Toni Williamson
-
Patent number: 9555048Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: August 18, 2014Date of Patent: January 31, 2017Assignee: FLEXION THERAPEUTICS, INC.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Patent number: 9555047Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: August 18, 2014Date of Patent: January 31, 2017Assignee: FLEXION THERAPEUTICS, INC.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20150025050Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: August 18, 2014Publication date: January 22, 2015Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20140356437Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: August 18, 2014Publication date: December 4, 2014Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Patent number: 8828440Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: GrantFiled: March 16, 2012Date of Patent: September 9, 2014Assignee: Flexion Therapeutics, Inc.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20140242170Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: December 16, 2013Publication date: August 28, 2014Applicant: FLEXION THERAPEUTICS, INC.Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20120288534Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: March 16, 2012Publication date: November 15, 2012Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Publication number: 20120282298Abstract: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid arthritis. Corticosteroid microparticle formulations are administered locally as a sustained release dosage form (with or without an immediate release component) that results in efficacy accompanied by clinically insignificant or no measurable effect on endogenous cortisol production.Type: ApplicationFiled: February 8, 2012Publication date: November 8, 2012Inventors: Neil Bodick, Robert C. Blanks, Anjali Kumar, Michael D. Clayman, Mark Moran
-
Patent number: 4945476Abstract: A knowledge base having particular utility as a medical/pathology knowledge base contains textual and pictorial information on various diseases. The knowledge base includes user-selectable designations of diagnostic features which are characteristic of respective conditions to be diagnosed. These features comprise a case record and several case records are stored and retrieved for subsequent display of the features therein and of one or more pictorial images of those features. The pictorial images preferably are stored on a device such as an optical disk; and these pictorial images are linked to case records which may be stored in other storage devices, such as magnetic disk, whereby the retrieval of a case record accesses the linked pictorial images, whereby those pictorial images and features of the case record are displayed.Type: GrantFiled: February 26, 1988Date of Patent: July 31, 1990Assignee: Elsevier Science Publishing Company, Inc.Inventors: Neil Bodick, Andre L. Marquis